In 2018 sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $80 billion across the major markets (United States, EU5, and Japan). Sales of biosimilars in these same therapy areas and regions totaled approximately $2.5 billion. Throughout our 2018-2028 forecast period, increasing numbers of branded biologics are set to lose patent protection, with biosimilars expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and region.

Table of contents

  • Overview of Biosimilars Forecasts
    • Overview of Biosimilar Forecasts
      • Total Major-Market Reference Brand and Biosimilar Market Shares
      • Biosimilar Erosion
    • Biosimilar Erosion Across the Major Markets
      • Definitions

Author(s): Hamzah Aideed, MSc; Jimmy Jacob; Marta Delgado, PhD

Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.  

Jimmy Jacob, is a Business Insights Analyst in the Biosimilars team. Prior to joining DRG, Jimmy worked as a Scientist in Medimmune and Horizon Discovery mostly involving CRIPSR/Cas9 therapeutics. He received his master’s degree in Biotechnology from University of Dundee and his from Imperial College London. His work involved identifying novel molecules that regulated oestrogen receptor-alpha in breast cancer.

Marta Delgado, is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a in Molecular Neuroscience from University College of London (UCL) and a in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.